Connect with us
BioNTech shares are off to a strong start in 2026, gaining over 21 percent in both European and U.S. markets. Analysts remain optimistic, with most recommending...
In phase 3 trials, Pfizer and BioNTech's vaccine showed strong immune responses against influenza A and COVID-19 but failed to meet key objectives for influenza B....
BioNTech's revenues plummeted 78.1% in the first half of 2024, down to €316.3 million, due to decreased demand for Covid-19 vaccines and a seasonal sales lull....
BioNTech saw a sharp drop in profits, starting 2024 with a €315 million loss, down from a €502 million profit the previous year, and sales plummeting...
A week ago, BioNTech presented its billing forecasts for 2024, with the aim of reaching €3 billion. The figure represents a significant decrease in value compared...
BioNTech 's turnover in 2022 was €17.31 billion, which represented a decrease of 8.8%. By business segments, those from the marketing of medicines amounted to €17.2...
As vaccine sales for Novavax, Moderna, and BioNTech shift in line with a changing Covid-19 situation, the results are being felt in the stock markets. Here...